242 related articles for article (PubMed ID: 19364867)
1. Molecular analysis of the gyrA and gyrB quinolone resistance-determining regions of fluoroquinolone-resistant Clostridium difficile mutants selected in vitro.
Spigaglia P; Barbanti F; Louie T; Barbut F; Mastrantonio P
Antimicrob Agents Chemother; 2009 Jun; 53(6):2463-8. PubMed ID: 19364867
[TBL] [Abstract][Full Text] [Related]
2. Fluoroquinolone resistance in Clostridium difficile isolates from a prospective study of C. difficile infections in Europe.
Spigaglia P; Barbanti F; Mastrantonio P; Brazier JS; Barbut F; Delmée M; Kuijper E; R Poxton I; On Behalf Of The European Study Group On Esgcd
J Med Microbiol; 2008 Jun; 57(Pt 6):784-789. PubMed ID: 18480338
[TBL] [Abstract][Full Text] [Related]
3. High-level resistance to moxifloxacin and gatifloxacin associated with a novel mutation in gyrB in toxin-A-negative, toxin-B-positive Clostridium difficile.
Drudy D; Quinn T; O'Mahony R; Kyne L; O'Gaora P; Fanning S
J Antimicrob Chemother; 2006 Dec; 58(6):1264-7. PubMed ID: 17018563
[TBL] [Abstract][Full Text] [Related]
4. Molecular characterization of moxifloxacin resistance from Canadian Clostridium difficile clinical isolates.
Walkty A; Boyd DA; Gravel D; Hutchinson J; McGeer A; Moore D; Simor A; Suh K; Taylor G; Miller M; Mulvey MR;
Diagn Microbiol Infect Dis; 2010 Apr; 66(4):419-24. PubMed ID: 20226332
[TBL] [Abstract][Full Text] [Related]
5. Effects of exposure of Clostridium difficile PCR ribotypes 027 and 001 to fluoroquinolones in a human gut model.
Saxton K; Baines SD; Freeman J; O'Connor R; Wilcox MH
Antimicrob Agents Chemother; 2009 Feb; 53(2):412-20. PubMed ID: 18710908
[TBL] [Abstract][Full Text] [Related]
6. Effects of subinhibitory concentrations of antibiotics on colonization factor expression by moxifloxacin-susceptible and moxifloxacin-resistant Clostridium difficile strains.
Denève C; Bouttier S; Dupuy B; Barbut F; Collignon A; Janoir C
Antimicrob Agents Chemother; 2009 Dec; 53(12):5155-62. PubMed ID: 19805572
[TBL] [Abstract][Full Text] [Related]
7. Analysis of mutations in the gyrA and gyrB genes and their association with the resistance of Mycobacterium tuberculosis to levofloxacin, moxifloxacin and gatifloxacin.
Nosova EY; Bukatina AA; Isaeva YD; Makarova MV; Galkina KY; Moroz AM
J Med Microbiol; 2013 Jan; 62(Pt 1):108-113. PubMed ID: 23019190
[TBL] [Abstract][Full Text] [Related]
8. Clostridium difficile isolates resistant to fluoroquinolones in Italy: emergence of PCR ribotype 018.
Spigaglia P; Barbanti F; Dionisi AM; Mastrantonio P
J Clin Microbiol; 2010 Aug; 48(8):2892-6. PubMed ID: 20554809
[TBL] [Abstract][Full Text] [Related]
9. gyrA and gyrB mutations are implicated in cross-resistance to Ciprofloxacin and moxifloxacin in Clostridium difficile.
Dridi L; Tankovic J; Burghoffer B; Barbut F; Petit JC
Antimicrob Agents Chemother; 2002 Nov; 46(11):3418-21. PubMed ID: 12384345
[TBL] [Abstract][Full Text] [Related]
10. Fluoroquinolone resistance in Mycobacterium tuberculosis and mutations in gyrA and gyrB.
Von Groll A; Martin A; Jureen P; Hoffner S; Vandamme P; Portaels F; Palomino JC; da Silva PA
Antimicrob Agents Chemother; 2009 Oct; 53(10):4498-500. PubMed ID: 19687244
[TBL] [Abstract][Full Text] [Related]
11. Emergence of high-level fluoroquinolone resistance in emm6 Streptococcus pyogenes and in vitro resistance selection with ciprofloxacin, levofloxacin and moxifloxacin.
Malhotra-Kumar S; Van Heirstraeten L; Lammens C; Chapelle S; Goossens H
J Antimicrob Chemother; 2009 May; 63(5):886-94. PubMed ID: 19279051
[TBL] [Abstract][Full Text] [Related]
12. Mutations in the quinolone resistance determining region in Staphylococcus epidermidis recovered from conjunctiva and their association with susceptibility to various fluoroquinolones.
Yamada M; Yoshida J; Hatou S; Yoshida T; Minagawa Y
Br J Ophthalmol; 2008 Jun; 92(6):848-51. PubMed ID: 18460536
[TBL] [Abstract][Full Text] [Related]
13. In vitro pharmacodynamic activity of gatifloxacin, gemifloxacin, moxifloxacin and levofloxacin against Streptococcus pneumoniae containing specific mutations in DNA gyrase and topoisomerase IV.
Garrison MW; Schimmels JA; Madaras-Kelly KJ
Diagn Microbiol Infect Dis; 2003 Dec; 47(4):587-93. PubMed ID: 14711480
[TBL] [Abstract][Full Text] [Related]
14. Characterizations of clinical isolates of clostridium difficile by toxin genotypes and by susceptibility to 12 antimicrobial agents, including fidaxomicin (OPT-80) and rifaximin: a multicenter study in Taiwan.
Liao CH; Ko WC; Lu JJ; Hsueh PR
Antimicrob Agents Chemother; 2012 Jul; 56(7):3943-9. PubMed ID: 22508299
[TBL] [Abstract][Full Text] [Related]
15. Activities of mutant prevention concentration-targeted moxifloxacin and levofloxacin against Streptococcus pneumoniae in an in vitro pharmacodynamic model.
Allen GP; Kaatz GW; Rybak MJ
Antimicrob Agents Chemother; 2003 Aug; 47(8):2606-14. PubMed ID: 12878526
[TBL] [Abstract][Full Text] [Related]
16. Docking studies on novel analogues of 8 methoxy fluoroquinolones against GyrA mutants of Mycobacterium tuberculosis.
Anand RS; Somasundaram S; Doble M; Paramasivan CN
BMC Struct Biol; 2011 Dec; 11():47. PubMed ID: 22152119
[TBL] [Abstract][Full Text] [Related]
17. Effect of fluoroquinolone resistance mutation Thr-82→Ile on Clostridioides difficile fitness.
Vernon JJ; Wilcox MH; Freeman J
J Antimicrob Chemother; 2019 Apr; 74(4):877-884. PubMed ID: 30590496
[TBL] [Abstract][Full Text] [Related]
18. The tcdA-negative and tcdB-positive Clostridium difficile ST81 clone exhibits a high level of resistance to fluoroquinolones: a multi-centre study in Beijing, China.
Cheng JW; Liu C; Kudinha T; Xiao M; Fan X; Yang CX; Wei M; Liang GW; Shao DH; Xiong ZJ; Hou X; Yu SY; Wang Y; Yang QW; Su JR; Xu YC
Int J Antimicrob Agents; 2020 Jul; 56(1):105981. PubMed ID: 32330584
[TBL] [Abstract][Full Text] [Related]
19. Mutant prevention concentrations for single-step fluoroquinolone-resistant mutants of wild-type, efflux-positive, or ParC or GyrA mutation-containing Streptococcus pneumoniae isolates.
Smith HJ; Walters M; Hisanaga T; Zhanel GG; Hoban DJ
Antimicrob Agents Chemother; 2004 Oct; 48(10):3954-8. PubMed ID: 15388458
[TBL] [Abstract][Full Text] [Related]
20. Fluoroquinolone resistance in Streptococcus pneumoniae: area under the concentration-time curve/MIC ratio and resistance development with gatifloxacin, gemifloxacin, levofloxacin, and moxifloxacin.
LaPlante KL; Rybak MJ; Tsuji B; Lodise TP; Kaatz GW
Antimicrob Agents Chemother; 2007 Apr; 51(4):1315-20. PubMed ID: 17296740
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
